# Influenza Vaccine (Split Virion), Inactivated, Quadrivalent in Pregnant Women

> **NCT07211152** · PHASE3 · RECRUITING · sponsor: **Sinovac Biotech Co., Ltd** · enrollment: 150 (estimated)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** Participants will receive one dose of vaccine (0.5 mL) of Sinovac QIV
- **BIOLOGICAL:** Vaxigrip QIV

## Key facts

- **NCT ID:** NCT07211152
- **Lead sponsor:** Sinovac Biotech Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-13
- **Primary completion:** 2026-03
- **Final completion:** 2026-06
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2026-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07211152

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07211152, "Influenza Vaccine (Split Virion), Inactivated, Quadrivalent in Pregnant Women". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT07211152. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*